Search

everythinglearnresearchcommunity

for

Search:↓

A 20-year-old is experiencing hair thinning and is considering Clascoterone and Minoxidil as treatments, avoiding finasteride due to concerns about fertility and hormones. A suggestion was made to use Clascoterone for local DHT targeting and combine it with Minoxidil for maintenance and regrowth while avoiding systemic side effects.

A user shared their 1 year and 5 months update on using finasteride and minoxidil for hair loss, noting improved hair density but a still receding hairline. They mentioned being inconsistent with minoxidil initially and experiencing more hair shedding after starting it.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

The user has been using minoxidil 5% twice daily for a year and finasteride 0.5 mg daily for five months, seeing noticeable hair growth without side effects. They are considering adding microneedling with a derma roller or stamp to their routine for enhanced results.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Finasteride is expensive in Germany, but cheaper alternatives are available in other countries like Turkey, Greece, and Russia. Users suggest traveling to these countries or seeking online prescriptions to save money.

The conversation discusses hair loss treatments, specifically the use of finasteride and dutasteride. Users share experiences of shedding and varying effectiveness, with some suggesting adding minoxidil or a topical anti-androgen for better results.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

After 8 months of using topical finasteride and minoxidil, along with derma rolling twice a week with 1mm needles, significant hair regrowth was achieved. The user applies two drops of finasteride daily and distributes it with fingers.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

The conversation discusses unconventional methods for hair regrowth, including scalp trauma like burning or microneedling, and compares them to treatments like Minoxidil and Finasteride. It highlights skepticism about these methods and the body's unpredictable healing responses.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

Young men experiencing hair loss should consult a dermatologist and consider treatments like finasteride and minoxidil. Shaving is an option, but medications can help maintain and regrow hair, though results vary.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

A 48-year-old male experienced hair regrowth after using oral finasteride for 3 years, despite stopping due to side effects like depression and low energy. He achieved a fuller look with styling techniques and reported using organic shampoo and herbal treatments.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.

The user experienced hair regrowth with dutasteride but later lost progress despite using minoxidil foam and dermastamping. Suggestions included reducing dermastamping frequency, conducting blood tests, and considering oral minoxidil or different brands of dutasteride.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.